Go here to read the rest:
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

See the rest here:
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

Read the original post:
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early...

Originally posted here:
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of...

Read the original post:
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Go here to read the rest:
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated...

Continued here:
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

Read the original post:
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program

See the article here:
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

See original here:
Evn Introduces a Game-Changer in Cannabis Edibles with New Hemp-Derived Live Resin Gummies

See more here:
Better Choice Company To Effectuate a Reverse Stock Split

Read this article:
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

See the original post here:
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

More:
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Read the rest here:
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD...

See more here:
Ultimovacs ASA: Mandatory notification of trades by primary insider

Read the rest here:
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

More here:
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Originally posted here:
CRISPR Therapeutics Announces $280 Million Registered Direct Offering

See original here:
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024